Physician profile
Daniel James Liebertz
NPI 1740592849
$258.41
in general payments reported to CMS, 2019-2025
6 companies · $52.45 in 2025
The $52.45 reported for 2025 was less than what a typical Facial Plastic Surgery provider received nationally (typical 2025 total: $271).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.97 · 2020: $19.55 · 2021: $39.88 · 2023: $72.56 · 2025: $52.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $125.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $52.45 | 2025 | Daxxify |
| Abbvie INC. | $49.73 | 2023 | |
| Mentor Worldwide LLC | $44.31 | 2019 | |
| Sientra, INC. | $42.06 | 2020-2021 | |
| Allergan, INC. | $35.13 | 2019-2021 | |
| Galderma Laboratories, L.P. | $34.73 | 2019-2023 | Dysport |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Liebertz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.